Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Line item | Medel Sakartvelo | Neoparmi + | Jihelsi | Tbilisi Medic | New Pharma |
|---|---|---|---|---|---|
| Total Revenue | 16,323 | 16,295 | 15,588 | 14,805 | 14,604 |
| Total COGS | -12,884 | -11,672 | -9,121 | -9,886 | -6,524 |
| Gross Profit | 3,438 | 4,623 | 6,467 | 4,918 | 8,080 |
| Gross Margin | 21.1% | 28.4% | 41.5% | 33.2% | 55.3% |
| Total Operating Expenses | 2,116 | -5,374 | -1,404 | -4,091 | -8,129 |
| EBITDA | 5,555 | -751 | 5,063 | 827 | -27 |
| EBITDA Margin | 34.0% | -4.6% | 32.5% | 5.6% | -0.2% |
| Total D&A | -20 | -104 | -20 | -504 | -66 |
| EBIT / Operating Income | 5,535 | -855 | 5,043 | 323 | -535 |
| Total Other Income | 2,328 | -37 | 141 | -2,184 | -81 |
| Profit Before Tax | 7,863 | -873 | 5,179 | -2,055 | -1,003 |
| Total Income Tax | -4 | 0 | 0 | -34 | -217 |
| Net Profit / (Loss) | 5,461 | -873 | 5,179 | -2,194 | -1,220 |
| Net Margin | 33.5% | -5.4% | 33.2% | -14.8% | -8.4% |
| Total Interest Income | — | 21 | — | 4 | 78 |
| Total Interest Expense | — | -1 | -4 | -198 | -466 |
| Other Comprehensive Income | — | — | — | 303 | — |
| Total Comprehensive Income | — | — | — | -1,892 | — |
| Other Operating Income | — | — | — | — | 22 |
| Impairment (non-financial) | — | — | — | — | -442 |
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Medel Sakartvelo | Pharma | 34.0% | 82nd pct | 110 |
| Jihelsi | Pharma | 32.5% | 78th pct | 110 |
| Tbilisi Medic | Pharma | 5.6% | 24th pct | 110 |
| New Pharma | Pharma | -0.2% | 15th pct | 110 |
| Neoparmi + | Pharma | -4.6% | 9th pct | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.